What investors in pharma and biotech are looking for and how to meet those expectations
Download
1 / 6

What Investors in Pharma and Biotech are Looking for - PowerPoint PPT Presentation


  • 419 Views
  • Uploaded on

What Investors in Pharma and Biotech are Looking for (and how to Meet those Expectations). NSEP 1 st March 2005. Value Creation. Security Growth. Mentoring. Investors. Biotech. Newsflow pre and post funding. Confidence from  clinical success  roll out products  sales  value

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'What Investors in Pharma and Biotech are Looking for' - PamelaLan


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
What investors in pharma and biotech are looking for and how to meet those expectations l.jpg

What Investors in Pharma and Biotech are Looking for(and how to Meet those Expectations)

NSEP 1st March 2005


Slide2 l.jpg

Value

Creation

Security

Growth

Mentoring

Investors

Biotech

Newsflow pre

and post funding

  • Confidence from

  •  clinical success

  •  roll out products

  •  sales

  •  value

  •  efficiency on cash burn

  • Constraints

  • 30% have < 2 years cash

  • Management team

  • Reach


Proof of value l.jpg
Proof of Value

  • Point at which proof of value obtained is dependent upon:

    • Class of compound; is it well validated or unknown?

    • Ability of animal models utilised to predict human efficacy

    • Presence of validated surrogate marker or endpoint- how early in development can these be used to demonstrate effect?

    • Whether sufficient just to show that does not have the significant pharmacological AE’s of current treatments

    • Demonstration of developability


Proof of value alternative definitions l.jpg
Proof of Value:Alternative definitions


Proof of value5 l.jpg
Proof of Value

Supply and demand pressure on Pharma to in license earlier

Supply

Value

Unknown, unvalidated class

Known, validated class

Pressure on Biotech to license out earlier for validation

Demand

Risk

II

III

I

First Dose in Man

Proof of Principle

Proof of Concept


However as a young biotech are you l.jpg
However as a young Biotech are you…

  • Sustainable or just following fashion?

    • “hot agonist/antagonist” of the day

  • Selling the crown jewels?

  • Leaving enough in the pipeline to create value in the future?

  • Able to produce fuel/cash until the end game?


ad